Skip to main content

Advertisement

SpringerLink
Log in

Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

A two-year randomized, double-blind, placebo-controlled clinical trial used paired serum samples from 122 patients with primary biliary cirrhosis to compare the effect of ursodeoxycholic acid and colchicine on their immune parameters. IgG antibodies to pyruvate dehydrogenase, the major autoantigen in primary biliary cirrhosis, were determined by enzyme-linked immunosorbent assay and immunoblot; enzyme inhibition assay against pyruvate dehydrogenase was used to test the changes of the functional reactivity of the serum autoantibodies. Treatment with ursodeoxycholic acid decreased both the level of IgG antibodies to pyruvate dehydrogenase (P<0.01) and the inhibitory titer of the sera for pyruvate dehydrogenase (P<0.01). Treatment with colchicine or placebo showed no statistically significant changes in either the antibody levels or the inhibitory titers. Ursodeoxycholic acid thus alters the immune parameters of patients with primary biliary cirrhosis. The mechanism of these changes needs further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AMA :

Anti-mitochondrial antibodies

PBC :

Primary biliary cirrhosis

OD :

Optical density

PDH :

Pyruvate dehydrogenase

UDCA :

Ursodeoxycholic acid

References

  1. Kaplan MM (1993) New strategies needed for treatment of primary biliary cirrhosis. Gastroenterology 104:651–653

    Google Scholar 

  2. Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hübner K, Hellstern A, Gatzen M, Leuschner M (1989) Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled doubleblind trial. Gastroenterology 97:1268–1274

    Google Scholar 

  3. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW (1994) A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 9:162–168

    Google Scholar 

  4. Poupon RE, Baikau B, Eschwege E, Poupon R, UDCA-PBC Study Group (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 324:1548–1554

    Google Scholar 

  5. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, Lesage G, Rossi SS, Hofman AF (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106:1284–1290

    Google Scholar 

  6. Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315:1448–1454

    Google Scholar 

  7. Bodenheimer H, Schaffner F, Pezzullo J (1988) Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 95:124–129

    Google Scholar 

  8. Calmus Y, Gane P, Rouger P, Poupon R (1990) Hepatic expression of class I and II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11:12–15

    Google Scholar 

  9. Gershwin ME, Mackay IR, Sturgess A, Coppel RL (1987) Identification and specificity of a cDNA encoding the 70kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 138:3525–3531

    Google Scholar 

  10. Yeaman SJ, Fussey SPM, Danner DJ, James OFW, Mutimer DJ, Bassendine MF (1988) Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1:11067–11070

    Google Scholar 

  11. Yoshida T, Bonkovsky H, Ansari A, Danner D (1990) Anti-bodies against mitochondrial dehydrogenase complexes in primary biliary cirrhosis. Gastroenterology 99:187–194

    Google Scholar 

  12. Begley JP, Barry RE, Denton RM, Stansbie D (1991) Inhibition of the activity of the 2-oxoacid dehydrogenase complexes by sera from patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 3:365–369

    Google Scholar 

  13. Kisand K, Kisand K, Salupere V, Uibo R (1994) Enzyme-linked immunosorbent assays for the determination of IgG, IgA and IgM autoantibodies to pyruvate dehydrogenase in primary biliary cirrhosis. Int J Clin Lab Res 24:98–101

    Google Scholar 

  14. Yeaman SJ (1986) The mammalian 2-oxoacid dehydrogenases: a complex family. Trends Biochem Sci 11:293–296

    Google Scholar 

  15. Vuoristo M, Färkkilä M, Karvonen A-L, Leino R, Lehtola J, Mäkinen J, Mattila J, Friman C, Seppälä K, Tuominen J, Miettinen TA (1995) A placebo controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 108:1470–1478

    Google Scholar 

  16. Laemlli UK, Favre M. Maturation of the head of bacteriophage T4 (1973) J Mol Biol 80:575–599

    CAS  PubMed  Google Scholar 

  17. Teoh KL, Rowley MJ, Zafirakis H, Dickson ER, Wiesner RH, Gershwin ME, Mackay IR (1994) Enzyme inhibitory autoanti-bodies to pyruvate dehydrogenase complex in primary biliary cirrhosis: applications of a semiautomated assay. Hepatology 20:1220–1224

    Google Scholar 

  18. Teoh K-L, Mackay IR, Rowley MJ, Fussey SPM (1994) Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis differ for mammalian, yeast and bacterial enzymes: implications for molecular mimicry. Hepatology 19:1029–1033

    Google Scholar 

  19. Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, Guedes LH, Gershwin ME, Shoenfeld Y (1994) Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J Clin Immunol 14:14–19

    Google Scholar 

  20. Klein R, Wiebel M, Engelhart S, Berg PA (1993) Sera from patients with tuberculosis recognize the M2a-epitope (E2-subunit of pyruvate dehydrogenase) specific for primary biliary cirrhosis. Clin Exp Immunol 92:308–316

    Google Scholar 

  21. Krams SM, Van de Water J, Coppel RL, Esquivel C, Roberts J, Ansari A, Gershwin ME (1990) Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology 12:306–313

    Google Scholar 

  22. Van de Water J, Ansari A, Surh CD, Coppel R, Röche T, Bonkovsky H, Kaplan M, Gershwin ME (1991) Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 146:89–94

    Google Scholar 

  23. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, Coppel R, Ansari A, Nakanuma Y, Gershwin ME (1993) Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 91:2653–2664

    Google Scholar 

  24. Gershwin ME, Mackay IR (1991) Primary biliary cirrhosis: paradigma or paradox for autoimmunity. Gastroenterology 100:822–833

    Google Scholar 

  25. Stiehl A, Rudolph G, Raedsch R, Möller B, Hopf U, Lotterer E, Bircher J, Folsch U, Klaus J, Endete R, Senn M (1990) Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 12:492–497

    Google Scholar 

  26. Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. (1992) Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 103:617–621

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Institute of General and Molecular Pathology, University of Tartu, Veski str.34, EE-2400, Tartu, Estonia

    K. E. Kisand & R. Uibo

  2. Tampere University Hospital, Finland

    A. L. Karvonen & J. Inkovaara

  3. Helsinki University Hospital, Finland

    M. Vuoristo, M. Färkkilä & T. Miettinen

  4. University of Tampere, Finland

    K. Krohn

  5. University of Oulu, Finland

    J. Lehtola

Authors
  1. K. E. Kisand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. L. Karvonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Vuoristo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Färkkilä
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Lehtola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Inkovaara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Miettinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Krohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Uibo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kisand, K.E., Karvonen, A.L., Vuoristo, M. et al. Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis. J Mol Med 74, 269–274 (1996). https://doi.org/10.1007/BF00196579

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00196579

Key words

Search

Navigation